Emerging Opportunities for Serotypes of Botulinum Neurotoxins

Background: Two decades ago, botulinum neurotoxin (BoNT) type A was introduced to the commercial market. Subsequently, the toxin was approved by the FDA to address several neurological syndromes, involving muscle, nerve, and gland hyperactivity. These syndromes have typically been associated with ab...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Peng Chen, Zhongxing, Morris, J. Glenn, Rodriguez, Ramon L., Shukla, Aparna Wagle, Tapia-Núñez, John, Okun, Michael S.
Формат: Artigo
Язык:Inglês
Опубликовано: MDPI 2012
Предметы:
Review
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC3509704/
https://ncbi.nlm.nih.gov/pubmed/23202312
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/toxins4111196
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы